Interxion (INXN) Misses Q3 EPS by 3c; Boosts FY17 Revenue Outlook
Get Alerts INXN Hot Sheet
Join SI Premium – FREE
*Assumes Exchange Rate of 1 Euro = 1.16 USD
Interxion (NYSE: INXN) reported Q3 EPS of $0.16*, $0.03 worse than the analyst estimate of $0.19. Revenue for the quarter came in at $145.05* million versus the consensus estimate of $145.26 million.
Business Outlook
Interxion is updating its guidance for full year 2017, increasing its full year revenue guidance, narrowing Adjusted EBITDA guidance to the top end of its previously announced range, and reaffirming capital expenditures (including intangibles) guidance
Financial Highlights
- Revenue increased by 18% to €124.6 million (3Q 2016: €105.3 million).
- Recurring revenue1 increased by 17% to €117.4 million (3Q 2016: €100.0 million).
- Net income decreased by 4% to €10.1 million (3Q 2016: €10.5 million).
- Adjusted net income2 increased by 24% to €10.7 million (3Q 2016: €8.6 million).
- Earnings per diluted share decreased to €0.14 (3Q 2016: €0.15).
- Adjusted earnings2 per diluted share increased to €0.15 (3Q 2016: €0.12).
- Adjusted EBITDA2 increased by 16% to €56.2 million (3Q 2016: €48.3 million).
- Adjusted EBITDA margin decreased to 45.1% (3Q 2016: 45.9%).
- Capital expenditures, including intangible assets3, were €75.2 million (3Q 2016: €64.5 million).
Operating Highlights
- Equipped space4 increased by 1,900 square metres in the quarter to 118,900 square metres.
- Revenue generating space4 increased by 2,100 square metres in the quarter to 97,100 square metres.
- Utilisation rate at the end of the quarter was 82%.
- During the third quarter, Interxion completed the following major expansions:
- 1,100 sqm expansion in Frankfurt,
- 300 sqm expansion in Stockholm, and
- 400 sqm expansion in Zurich.
For earnings history and earnings-related data on Interxion (INXN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share